The structure of the paraquat story is not complicated: a chemical banned by dozens of countries — including by the government of the company's own Chinese parent — continued expanding across American farmland because the company that profited most from it selectively managed what regulators knew. Roughly 3,700 pages of newly released court documents show Syngenta possessed internal analyses on dermal absorption rates, surfactant-enhanced skin penetration, and neurological risks that it did not submit to the EPA, despite federal law requiring disclosure of information about 'unreasonable adverse effects.' The scale of the regulatory gap is striking. Between 2000 and 2018, US paraquat use nearly tripled even as Sweden, China, the EU, and ultimately more than 60 nations pulled it from their markets. Syngenta acknowledged in a January 2025 discovery document that it had no record of providing the EPA with a long list of reports pertaining to paraquat's health impacts. The company insists none of this information was 'relevant' to the US market — a claim that strains credulity given that dermal absorption and neurotoxicity operate the same way regardless of geography. The informational asymmetry is the load-bearing element. Syngenta focused its outward-facing scientific strategy on developing and promoting studies demonstrating safety — one 2016 paper was internally described as 'invaluable in supporting our work' — while withholding data on how fast paraquat penetrates untreated clothing and enters the bloodstream. This is not a case of ambiguous science being interpreted differently. It is a case of the regulated entity curating the information the regulator was allowed to see. The EPA's response has been characteristic: passive, procedural, and slow. The agency said in June it would hold a summer roundtable to re-examine paraquat safety. As of publication, no such event has been held or scheduled. The agency acknowledged it 'cannot speculate on how this additional information would impact EPA's assessment' and stated that failure to submit required data 'is a direct violation of federal law' — without indicating any enforcement action. The litigation landscape adds a layer of institutional consequence. Syngenta has already paid at least $187 million in a 2021 settlement with no admission of liability, plus undisclosed additional settlement amounts since. Thousands of Parkinson's cases remain active. The company announced earlier this year it would halt all global paraquat production — but other suppliers continue selling in the US under EPA approval. A June 2025 Supreme Court ruling declaring the EPA the pre-emptive authority on pesticide warning labels makes the information gap even more consequential. If the EPA is now the sole gatekeeper for health warnings, and the EPA's assessments were built on an incomplete dataset curated by the registrant, the entire regulatory architecture rests on a foundation the regulated entity helped hollow out. Stanford epidemiologist Tracey Woodruff put it plainly: when companies know from their own studies that their products are harmful and don't tell regulators, 'they are knowingly contributing to people getting sick and dying.' The paraquat story is a structural failure, not an aberration. FIFRA's self-reporting model places the burden of disclosure on the company with the most to lose from disclosure. Without independent monitoring, proactive enforcement, or mandatory real-time data sharing, the system defaults to whatever the registrant decides is 'relevant.' For two decades, Syngenta decided that internal data on brain damage, skin absorption, and surfactant risks was not relevant to the American regulator. The EPA, by its own admission, never knew what it didn't have.
